{"gene":"CX3CL1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2007,"finding":"CX3CL1 is sequentially processed by alpha-secretase (ADAM10) and then gamma-secretase, generating C-terminal fragments (CTFs). ADAM10-mediated ectodomain shedding at multiple cleavage sites releases the soluble chemokine domain, and inhibitor studies plus presenilin 1/2-deficient cell lines established gamma-secretase (but not beta-secretase) involvement in processing the remaining CTF, analogous to Notch/E-cadherin processing.","method":"Inhibitor studies, presenilin 1/2 knockout cell lines, CX3CL1 constructs C-terminally fused to 2Z-tag for CTF detection, Western blotting","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal approaches (genetic knockout cells, pharmacological inhibitors, tagged constructs) in a single rigorous mechanistic study","pmids":["17467666"],"is_preprint":false},{"year":2020,"finding":"CX3CL1 forms homo-oligomers of 3–7 monomers driven by its transmembrane domain. The transmembrane peptide self-associates in both cellular and acellular lipid environments (while a scrambled version does not), and a transmembrane peptide inhibitor blocks both CX3CL1 oligomerization and its adhesive function, demonstrating that oligomerization is required for cell-to-cell adhesion.","method":"Native electrophoresis, single-molecule fluorescence kinetics, FRAP assays with transmembrane peptides in cells and liposomes, molecular modeling, adhesion inhibition assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal biophysical methods in a single study demonstrating structure-function relationship","pmids":["32494000"],"is_preprint":false},{"year":2019,"finding":"The CX3CL1 intracellular domain (CX3CL1-ICD), released by sequential α-, β-, and γ-secretase cleavage, translocates to the cell nucleus and alters gene expression (back-signaling). Overexpression of the CX3CL1 C-terminal fragment in 5xFAD Alzheimer mice reduced amyloid deposition and neuronal loss; this effect was attributed to enhanced neurogenesis through activation of the TGFβ2/3-Smad2/3 pathway and was independent of CX3CR1 binding.","method":"Transgenic mouse overexpression, morphological and unbiased RNA-sequencing analyses, immunofluorescence, genetic epistasis in 5xFAD model","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with RNA-seq pathway validation, single lab","pmids":["31209068"],"is_preprint":false},{"year":2019,"finding":"CX3CL1 overexpression in neurons (Tg-CX3CL1 mice) enhances adult neurogenesis in subgranular and subventricular zones via upregulation of TGF-β2 and TGF-β3 and activation of downstream Smad2 signaling. Neuronal deletion of Smad2 mitigated CX3CL1-enhanced neurogenesis, placing CX3CL1 upstream of TGF-β2/3-Smad2 in the neurogenesis pathway.","method":"Transgenic mouse overexpression, Smad2 conditional knockout, crossing with PS19 tau mice, behavioral testing, genetic epistasis","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with multiple transgenic crosses and behavioral readouts, single lab","pmids":["31822518"],"is_preprint":false},{"year":2020,"finding":"Soluble CX3CL1 (sFKN) and membrane-bound CX3CL1 (mFKN) exhibit differential activities in vivo: AAV-delivered sFKN fully rescued hippocampal neurogenesis, long-term potentiation, and both long-term and spatial memory deficits in CX3CL1-knockout mice, whereas mFKN only partially restored spatial learning and did not rescue long-term memory or neurogenesis.","method":"CX3CL1 knockout mice, AAV gene delivery of two CX3CL1 isoforms, behavioral cognitive testing, hippocampal neurogenesis assays, LTP electrophysiology","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with isoform-specific rescue, multiple functional readouts, single lab","pmids":["32410624"],"is_preprint":false},{"year":2006,"finding":"In polarized renal tubular epithelial cells (MDCK), CX3CL1 is targeted to and immobilized at the apical membrane. Apical targeting depends on N-linked glycosylation but not on the intracellular domain, lipid raft association, O-glycosylation, or direct actin cytoskeleton association (FRAP and fractionation showed membrane immobility but triton-soluble partitioning). Apically localized CX3CL1 enhanced CX3CR1-expressing leukocyte adhesion to the luminal surface.","method":"MDCK cell polarization, GFP-tagged CX3CL1, FRAP, cholesterol depletion, N-glycosylation inhibition, triton fractionation, leukocyte adhesion assays","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (FRAP, fractionation, glycosylation mutants, functional adhesion assay) in single study","pmids":["17151328"],"is_preprint":false},{"year":2008,"finding":"Thrombin induces endothelial CX3CL1 expression via protease-activated receptor 1 (PAR1) activation and downstream NF-κB signaling. Membrane-anchored CX3CL1 induced on HUVEC by thrombin triggers monocyte adhesion and enhanced CCL2/MCP-1 release by monocytes, potentiating transendothelial migration. The effect was blocked by NF-κB inhibitors and a PAR1 antagonist.","method":"RT-PCR, Western blot, flow cytometry, EMSA, ELISA, PAR1 agonist peptide, PAR1 antagonist SCH79797, IκB kinase inhibitor, dominant-negative IκBα overexpression, co-culture adhesion and migration assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal mechanistic approaches (genetic overexpression, pharmacological inhibition, signaling readouts, functional assays) in a single study","pmids":["18436581"],"is_preprint":false},{"year":2012,"finding":"ERK pathway activation and ADAM17 (and MMPs) are required for ethanol-induced CX3CL1 shedding/release from pancreatic stellate cells. Ethanol and phorbol ester synergistically increase CX3CL1 release via ERK and ADAM17 activation; specific inhibitors of ERK, MMP, and ADAM each suppressed CX3CL1 release.","method":"Primary rat pancreatic stellate cell culture, real-time RT-PCR, Western blot, ELISA, ERK/MMP/ADAM pharmacological inhibitors","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitor dissection with multiple targets, single lab","pmids":["23147224"],"is_preprint":false},{"year":2008,"finding":"CX3CL1 treatment of trophoblast cells (AC1M-88) increases adhesion to fibronectin and regulates expression of more than 30 ECM/adhesion genes including α-catenin (CTNNA1), osteopontin (SPP1), integrin α6 (ITGA6), MMP12, integrin β5 (ITGB5), and ECM1, demonstrating that CX3CL1 promotes trophoblast migration by altering adhesion molecule and ECM profiles.","method":"Pathway-specific oligoarrays, quantitative real-time RT-PCR, fibronectin adhesion assay, immunohistochemistry of first-trimester implantation sites","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene expression arrays validated by qPCR and functional adhesion assay, single lab","pmids":["18367676"],"is_preprint":false},{"year":2003,"finding":"CX3CL1 regulates NK cell activity in vivo: blocking anti-CX3CL1 or anti-CX3CR1 antibodies reduced NK-mediated clearance of YAC-1 tumor cells by 4–5 fold in mice. NK cell binding to activated endothelial monolayers was significantly inhibited by anti-CX3CR1 antibody or soluble CX3CL1. No direct effect on in vitro NK cytolytic activity was detected, indicating the effect operates through adhesion/trafficking rather than direct cytotoxicity.","method":"In vivo radiolabeled tumor cell clearance model, anti-CX3CL1/CX3CR1 antibody blocking, in vitro NK cytolysis assay, endothelial adhesion assay","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo blocking experiments with multiple antibodies and functional readouts, single lab","pmids":["14698146"],"is_preprint":false},{"year":2014,"finding":"CX3CR1 expression by both Th2 and Th1 CD4+ T cells is required for atopic dermatitis (AD) pathology. CX3CR1 deficiency or CX3CL1 blockade profoundly reduced AD but not psoriasis. Adoptive transfer experiments established that CX3CR1 controls CD4+ T cell retention in inflamed skin (not antigen presentation or T cell proliferation), identifying a novel function for this chemokine receptor distinct from its role in asthma where it regulates T cell survival.","method":"CX3CR1-deficient mice, CX3CL1 blocking antibody, adoptive transfer of CX3CR1-deficient T cells, murine AD and psoriasis models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO + adoptive transfer) with disease-specific phenotypic readouts; mechanism (retention vs. survival/proliferation) dissected by orthogonal experiments","pmids":["24821910"],"is_preprint":false},{"year":2011,"finding":"Exogenous CX3CL1 (fractalkine) protects striatal neurons from synergistic morphine + HIV-1 Tat-induced dendritic loss and death through CX3CR1 on microglia: antibody blockade of CX3CR1 mimicked the toxicity, and CX3CL1 failed to protect neurons co-cultured with CX3CR1-null glia, demonstrating that neuroprotection requires glial CX3CR1. CX3CL1 also normalized elevated microglial motility caused by Tat/morphine.","method":"Wild-type and Cx3cr1 knockout mouse co-cultures, time-lapse digital microscopy, antibody blockade, ELISA, immunofluorescence, Western blot","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (CX3CR1 KO glia) combined with pharmacological rescue and time-lapse tracking, single lab","pmids":["22093090"],"is_preprint":false},{"year":2018,"finding":"CX3CL1 activates the Src/FAK signaling pathway in prostate cancer cells through the Tyr992 residue of EGFR phosphorylation, promoting cell proliferation, migration, invasion and inhibiting apoptosis; kinase inhibitors of Src and FAK blocked CX3CL1-induced migration, and CX3CR1 overexpression promoted spinal metastasis in an in vivo mouse model.","method":"Western blot for Src/FAK phosphorylation, siRNA knockdown, kinase inhibitors, Transwell migration/invasion assays, in vivo mouse spinal metastasis model","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway activation by Western blot + inhibitor rescue + in vivo validation, single lab","pmids":["30066854"],"is_preprint":false},{"year":2019,"finding":"CX3CL1 promotes lung cancer cell (H460) migration and invasion via time-dependent activation of the Src/FAK signaling pathway; blocking Src with saracatinib prevented CX3CL1-mediated migration and invasion without affecting proliferation.","method":"Western blot for Src/FAK phosphorylation time-course, Transwell migration/invasion assays, saracatinib pharmacological inhibition","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase pathway activation confirmed by Western blot with pharmacological rescue, single lab","pmids":["30628679"],"is_preprint":false},{"year":2010,"finding":"Endogenous CX3CL1 negatively regulates glioma cell invasion by promoting tumor cell aggregation; neutralizing anti-CX3CL1 antibody delayed tumor aggregation and increased invasiveness. TGF-β1 decreases CX3CL1 mRNA and protein expression in glioma cells (confirmed by both recombinant TGF-β1 treatment and TGF-β1 siRNA knockdown), suggesting TGF-β1-mediated reduction of CX3CL1 contributes to glioma invasiveness.","method":"Neutralizing anti-CX3CL1 monoclonal antibody, recombinant TGF-β1 treatment, siRNA knockdown of TGF-β1, RT-PCR, Western blot, cell adhesion and invasion assays","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional antibody neutralization + siRNA genetic manipulation, single lab","pmids":["20511186"],"is_preprint":false},{"year":2020,"finding":"ADAM17-activated by MAPK14 (p38) in bone marrow endothelial cells (BMECs) mediates CX3CL1 shedding and release of soluble CX3CL1, which then promotes migration and invasion of hepatocellular carcinoma cells; neutralization of CX3CL1 inhibited BMEC-enhanced tumor cell migration. CX3CL1 activates the Src/PTK2 signaling axis and downstream PIK3CA/AKT and RHOA/ROCK2 pathways in HCC cells.","method":"Neutralizing antibody, Western blot for signaling pathway activation, Transwell assays, MAPK14 activation studies, in vivo mouse spinal metastasis model with CX3CR1 overexpression","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway readouts with neutralization rescue and in vivo validation, single lab","pmids":["32319605"],"is_preprint":false},{"year":2024,"finding":"Platelet-derived TLR4/NF-κB signaling increases ADAM10 expression in HCC tumor cells; ADAM10 then catalyzes CX3CL1 shedding, and the released CX3CL1 binds CX3CR1 to induce epithelial-mesenchymal transition and activate RhoA signaling, promoting tumor cell migration, invasion, and endothelial permeability. TLR4 knockdown or ADAM10 inhibition blocked platelet-enhanced tumor metastasis in vivo.","method":"TLR4 siRNA knockdown, ADAM10 inhibition, Western blot, Transwell migration/invasion assays, endothelial permeability assay, in vivo mouse lung metastasis model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown + pharmacological inhibition + in vivo validation, single lab","pmids":["38280480"],"is_preprint":false},{"year":2012,"finding":"Angiotensin II induces functional CX3CL1 expression in arterial (but not venous) endothelial cells through TNF-α and Nox5/ERK1/2/p38 MAPK/NF-κB signaling, leading to mononuclear cell adhesion. Knockdown of TNF-α or Nox5 with siRNA, or pharmacological inhibition of ERK1/2, p38, or NF-κB, abolished Ang-II-induced CX3CL1 upregulation and monocyte arrest. CX3CR1-deficient mice showed 83% reduction in arteriolar leukocyte adhesion.","method":"siRNA knockdown, pharmacological inhibitors (ERK1/2, p38, NF-κB), in vivo CX3CR1-deficient mice, human umbilical arterial vs. venous endothelial cells, mononuclear cell adhesion assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (siRNA, KO mice) and pharmacological dissection with multiple pathway targets and functional adhesion readout, arterial vs. venous specificity established","pmids":["23117657"],"is_preprint":false},{"year":2003,"finding":"In glomerulonephritis, activated mesangial cells are a major source of upregulated CX3CL1; TNF-α, IL-1β, PDGF-AB, and bFGF all upregulate CX3CL1 mRNA and protein in cultured mesangial cells. This cytokine/growth factor-stimulated expression is abolished by NF-κB inhibitors (curcumin, MG132), establishing NF-κB as the required transcriptional mediator.","method":"Northern blot, Western blot, RT-PCR, in situ hybridization combined with immunohistochemistry, NF-κB inhibitors (curcumin, MG132), rat anti-Thy1 glomerulonephritis model","journal":"Nephrology, dialysis, transplantation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro NF-κB inhibitor studies validated in vivo by ISH/IHC cell-type identification, single lab","pmids":["14605272"],"is_preprint":false},{"year":2019,"finding":"AAV8-delivered soluble CX3CL1 (sCX3CL1) significantly prolongs cone photoreceptor survival and improves visual function in three RP mouse strains. Pharmacological depletion of ~99% of microglia failed to abrogate the cone-rescue effect, demonstrating that sCX3CL1 acts via a pathway that does not require normal microglial numbers.","method":"AAV8 subretinal injection, three RP mouse strains, pharmacological microglia depletion, RNA sequencing of microglia, visual function testing","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, pharmacological epistasis, transcriptomics in a single comprehensive study","pmids":["31036641"],"is_preprint":false},{"year":2019,"finding":"CX3CL1 directly induces platelet migration in vitro; CX3CR1/Syk/PI3K pathway components are essential for CX3CL1-induced platelet migration. Hypoxia enhances platelet migration by upregulating CX3CL1 expression in HCC cells. CX3CL1 knockdown in HCC cells reduced platelet infiltration both in vitro and in an orthotopic HCC mouse model.","method":"Platelet migration assay, CX3CR1/Syk/PI3K inhibitors, CX3CL1 knockdown, hypoxia treatment, orthotopic HCC mouse model","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection + genetic knockdown + in vivo validation, single lab","pmids":["32799418"],"is_preprint":false},{"year":2024,"finding":"YTHDF2 (an m6A reader) in peritumoral hepatocytes stabilizes CX3CL1 transcripts in an m6A-dependent manner, increasing CX3CL1 expression and CD8+ T cell recruitment to suppress liver tumor growth. Oxaliplatin upregulates YTHDF2 expression via the cGAS-STING pathway, linking chemotherapy-induced innate immune signaling to CX3CL1-mediated adaptive immune responses.","method":"Liver-specific Ythdf2 knockout mice, tumor-bearing mouse models, m6A-dependent mRNA stability assays, cGAS-STING pathway analysis, CD8+ T cell recruitment quantification","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with mechanistic pathway (m6A/YTHDF2/CX3CL1) and functional immune readout, single lab","pmids":["39237909"],"is_preprint":false},{"year":2024,"finding":"Neuronal cathepsin S (CTSS) overexpression activates the CX3CL1-CX3CR1 axis (and JAK2-STAT3 pathway) to drive microglial activation toward M1 pro-inflammatory phenotype, worsening brain inflammation in aging and AD. The selective CTSS inhibitor LY3000328 rescued AD-related pathological features in APP/PS1 mice. CTSS was further shown to alter cathepsin B and L activities in microglia.","method":"CTSS overexpression in neurons, FACS, transcriptome (RNA-seq), CTSS inhibitor LY3000328, APP/PS1 mouse model, immunofluorescence","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic overexpression + pharmacological inhibition + transcriptomic pathway validation in vivo, single lab","pmids":["39453382"],"is_preprint":false},{"year":2013,"finding":"CX3CR1-CX3CL1 interaction in peritoneal fibrosis: CX3CL1 on peritoneal mesothelial cells interacts with CX3CR1-expressing macrophages in a positive feedback loop—macrophage cytokines (IL-1β) promote mesothelial CX3CL1 and TGF-β expression; TGF-β in turn upregulates CX3CR1 in monocytic cells. CX3CR1 deficiency or deletion protected against dialysate-induced peritoneal fibrosis in mouse models.","method":"CX3CR1-deficient mice, peritoneal dialysis mouse model, bone marrow transplantation, in vitro cytokine stimulation of mesothelial/monocytic cells, Western blot","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO + bone marrow transplant + in vitro mechanistic dissection, single lab","pmids":["30948201"],"is_preprint":false},{"year":2022,"finding":"CX3CL1 inhibition in cisplatin-induced acute kidney injury reduces podocyte ferroptosis by attenuating intracellular iron overload, lipid peroxidation (MDA, ROS), and mitochondrial dysfunction, while preserving GPX4 and XCT activity. CX3CL1 inhibition also attenuated endoplasmic reticulum stress (GRP78/eIF2α/CHOP pathway) and HIF-1α/HO-1 expression in podocytes in vitro and in vivo.","method":"CX3CL1 knockout mice, cisplatin model, RNA-seq, Western blot, immunofluorescence, in vitro podocyte cisplatin treatment, transmission electron microscopy for mitochondria","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout + in vitro mechanistic studies + RNA-seq pathway analysis, single lab","pmids":["37875838"],"is_preprint":false},{"year":2016,"finding":"Noradrenaline induces CX3CL1 protein and mRNA accumulation in primary cortical neurons and increases soluble CX3CL1 levels independent of ADAM10/ADAM17 activity. Noradrenaline-treated neurons showed enhanced dendritic arborization with CX3CL1 accumulating at dendritic bifurcations. The soluble CX3CL1 produced reduced nitrite accumulation in microglia, demonstrating a noradrenaline→neuronal CX3CL1→microglial anti-inflammatory signaling pathway.","method":"Primary cortical neuron cultures, ADAM10/ADAM17 inhibitors, RT-PCR, Western blot, ELISA for soluble CX3CL1, nitrite accumulation assay in microglia, immunofluorescence for dendritic morphology","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitor dissection + functional neuron-microglia co-culture readout, single lab","pmids":["27923568"],"is_preprint":false},{"year":2019,"finding":"IFN-γ and IL-1β or TNF-α synergistically upregulate CX3CL1 expression in first-trimester decidual cells via MEK1/2, JNK, and NF-κB signaling pathways; specific inhibitors of each pathway suppressed CX3CL1 production. CX3CL1 elicited concentration-dependent enhancement of CD56brightCD16- NK cell migration in chemotaxis assays.","method":"Primary human first-trimester decidual cell cultures, cytokine stimulation, MEK1/2/JNK/NF-κB pharmacological inhibitors, ELISA, qRT-PCR, NK cell chemotaxis assay","journal":"Reproductive sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling inhibitors in primary human cells + functional chemotaxis assay, single lab","pmids":["30606080"],"is_preprint":false},{"year":2022,"finding":"CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through the NF-κB signaling pathway in ankylosing spondylitis; NF-κB inhibitor BAY-117082 prevented M1 polarization and osteoclast differentiation, and anti-CX3CL1 monoclonal antibody alleviated disease in AS model mice.","method":"In vitro macrophage polarization assays, osteoclast differentiation assays, NF-κB inhibitor, anti-CX3CL1 neutralizing antibody, AS mouse model, histological assessment","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibition + antibody blockade + in vivo model, single lab","pmids":["37626378"],"is_preprint":false},{"year":2021,"finding":"CX3CL1-CX3CR1 signaling deficiency (Cx3cr1 knockout or Cx3cl1 knockdown) exacerbates obesity-induced adipose tissue inflammation and insulin resistance by reducing M2-polarized macrophage migration and causing M1-dominant shift in epididymal white adipose tissue. Bone marrow transplantation from Cx3cr1-/- donors was sufficient to impair glucose tolerance and insulin sensitivity; in vivo Cx3cl1 administration attenuated glucose intolerance.","method":"Cx3cr1 knockout mice, bone marrow transplantation, high-fat diet and leptin-deficient mouse models, flow cytometry, glucose tolerance and insulin tolerance tests","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO + bone marrow transplant establishes cell-autonomous mechanism, multiple models, single lab","pmids":["33765141"],"is_preprint":false},{"year":2024,"finding":"CX3CL1 release is specifically associated with immunogenic apoptosis (induced by mitoxantrone) but not ferroptosis or accidental necrosis. Addition of recombinant CX3CL1 to non-immunogenic apoptotic cancer cells in a prophylactic tumor vaccination model induced a robust anti-tumor immune response and improved mouse survival, demonstrating that CX3CL1 functions as a 'find me' signal enhancing immunogenicity of apoptosis.","method":"Luminex multiplex cytokine quantification, murine fibrosarcoma and melanoma cell lines, prophylactic vaccination mouse tumor model, comparison across death modalities","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue in vivo with recombinant protein + multi-modal cell death comparison, single lab","pmids":["39011040"],"is_preprint":false}],"current_model":"CX3CL1 (fractalkine) is a membrane-anchored transmembrane chemokine that undergoes sequential proteolytic processing—first by ADAM10/ADAM17 alpha-secretase activity to shed a soluble chemokine domain, then by gamma-secretase to release an intracellular domain (ICD) that translocates to the nucleus to regulate gene expression (including TGFβ2/3-Smad2-dependent neurogenesis); its transmembrane domain drives homo-oligomerization (3–7 monomers) that is required for its adhesion function; membrane-bound CX3CL1 mediates firm leukocyte adhesion to endothelium and promotes NK cell trafficking in vivo, while the soluble form acts as a chemoattractant for CX3CR1-expressing monocytes, T cells, NK cells, microglia, and platelets; CX3CL1 signals through the G-protein-coupled receptor CX3CR1 to activate Src/FAK, NF-κB, ERK, PI3K/AKT, and RhoA/ROCK pathways in diverse cellular contexts including cancer invasion, macrophage polarization (M1/M2), osteoclastogenesis, and microglial regulation; its expression in endothelial cells is induced by TNF-α, IL-1β, thrombin (via PAR1/NF-κB), angiotensin II (via Nox5/ERK/p38/NF-κB), and TLR3 signaling, while physiological shear stress suppresses this induction; in neurons, noradrenaline upregulates CX3CL1 independently of ADAM10/17, and CTSS-driven CX3CL1-CX3CR1 axis activation shifts microglia to a pro-inflammatory M1 state; in vivo, soluble CX3CL1 rescues cognitive deficits, hippocampal neurogenesis, and LTP in CX3CL1-knockout mice more effectively than membrane-bound CX3CL1, and AAV-delivered sCX3CL1 protects cone photoreceptors in retinitis pigmentosa via a microglia-independent mechanism."},"narrative":{"mechanistic_narrative":"CX3CL1 (fractalkine) is a membrane-anchored transmembrane chemokine that functions both as a cell-surface adhesion molecule and, after proteolytic release, as a soluble chemoattractant, thereby coupling vascular leukocyte recruitment to chemokine signaling across immune, neural, and tumor contexts [PMID:17467666, PMID:14698146]. Its activity is governed by regulated intramembrane proteolysis: ADAM10/ADAM17 alpha-secretase activity sheds the soluble chemokine domain, and gamma-secretase (presenilin-dependent, beta-secretase-independent) then cleaves the remaining C-terminal fragment to liberate an intracellular domain that translocates to the nucleus and reprograms gene expression [PMID:17467666, PMID:31209068]. Self-association of its transmembrane domain drives homo-oligomerization (3–7 monomers), which is required for cell-to-cell adhesion, while apical membrane targeting in polarized epithelium depends on N-glycosylation and supports luminal leukocyte capture [PMID:32494000, PMID:17151328]. The soluble and membrane-bound forms are functionally distinct in vivo: soluble CX3CL1 more fully restores hippocampal neurogenesis, LTP, and memory in knockout mice, and its nuclear C-terminal fragment promotes adult neurogenesis through a CX3CR1-independent TGFβ2/3–Smad2 axis [PMID:31209068, PMID:31822518, PMID:32410624]. Through its receptor CX3CR1, CX3CL1 activates Src/FAK, PI3K/AKT, and RhoA/ROCK signaling to drive cancer cell migration, invasion, and metastasis, and it directs leukocyte and platelet trafficking, M1/M2 macrophage polarization, osteoclastogenesis, and microglial phenotype [PMID:30066854, PMID:32319605, PMID:32799418, PMID:37626378]. Its endothelial and stromal expression is transcriptionally induced through NF-κB by pro-inflammatory and vasoactive stimuli including TNF-α, IL-1β, thrombin (via PAR1), and angiotensin II (via Nox5/ERK/p38), positioning CX3CL1 as a convergent effector of inflammatory and metastatic signaling [PMID:18436581, PMID:23117657, PMID:14605272].","teleology":[{"year":2003,"claim":"Established that CX3CL1 governs NK cell function through adhesion and trafficking rather than direct cytotoxicity, defining its core role as a vascular capture molecule.","evidence":"In vivo radiolabeled tumor clearance with anti-CX3CL1/CX3CR1 blockade plus endothelial adhesion and NK cytolysis assays in mice","pmids":["14698146"],"confidence":"Medium","gaps":["Did not resolve the soluble vs. membrane-bound contribution to NK adhesion","No molecular signaling pathway dissected"]},{"year":2006,"claim":"Showed how CX3CL1 is spatially positioned for leukocyte capture by defining the determinants of its polarized apical targeting in epithelium.","evidence":"GFP-tagged CX3CL1 in polarized MDCK cells with FRAP, glycosylation inhibition, fractionation, and leukocyte adhesion assays","pmids":["17151328"],"confidence":"High","gaps":["The trafficking machinery reading the N-glycan signal was not identified","Generalizability beyond renal epithelium untested"]},{"year":2007,"claim":"Defined the proteolytic logic of CX3CL1 by demonstrating sequential ADAM10/gamma-secretase processing analogous to Notch, establishing regulated intramembrane proteolysis as the switch between membrane and soluble forms.","evidence":"Presenilin 1/2 knockout cells, secretase inhibitors, and tagged CTF-detection constructs with Western blotting","pmids":["17467666"],"confidence":"High","gaps":["Fate and function of the released intracellular fragment not addressed here","Physiological triggers of cleavage in vivo not defined"]},{"year":2008,"claim":"Connected inflammatory protease signaling to CX3CL1 induction by showing thrombin/PAR1/NF-κB drives endothelial CX3CL1 and downstream monocyte adhesion.","evidence":"HUVEC stimulation with PAR1 agonist/antagonist, NF-κB inhibitors, dominant-negative IκBα, EMSA, and co-culture adhesion/migration assays","pmids":["18436581"],"confidence":"High","gaps":["In vivo relevance to thrombotic inflammation not tested","Did not separate soluble from membrane CX3CL1 contributions"]},{"year":2012,"claim":"Generalized NF-κB-dependent CX3CL1 induction to vasoactive signaling, with angiotensin II acting via TNF-α and Nox5/ERK/p38 in arterial but not venous endothelium.","evidence":"siRNA knockdown, pathway inhibitors, arterial vs. venous endothelial cells, and CX3CR1-deficient mice with adhesion readouts","pmids":["23117657"],"confidence":"High","gaps":["Basis of arterial-venous selectivity not molecularly defined","Link to atherosclerotic disease progression not directly tested"]},{"year":2019,"claim":"Revealed CX3CL1 back-signaling, showing the nuclear-translocating intracellular domain reduces Alzheimer pathology by enhancing neurogenesis through a receptor-independent TGFβ2/3–Smad2 axis.","evidence":"Transgenic CX3CL1-CTF overexpression in 5xFAD mice with RNA-seq, plus Tg-CX3CL1 mice crossed to Smad2 conditional knockouts and tau models","pmids":["31209068","31822518"],"confidence":"Medium","gaps":["Direct DNA-binding or transcriptional targets of the ICD not identified","How nuclear ICD activates TGFβ2/3 transcription is unresolved"]},{"year":2020,"claim":"Demonstrated that transmembrane-driven homo-oligomerization is mechanistically required for CX3CL1 adhesion, and that soluble and membrane forms are functionally non-equivalent in vivo.","evidence":"Biophysical TM-peptide self-association (native gels, single-molecule kinetics, FRAP) and adhesion inhibition; AAV isoform-specific rescue in CX3CL1-knockout mice with LTP/behavioral readouts","pmids":["32494000","32410624"],"confidence":"High","gaps":["Structural model of the oligomer interface not resolved","Mechanism behind superior soluble-form rescue of memory not defined"]},{"year":2020,"claim":"Established CX3CL1/CX3CR1 as a pro-metastatic axis, linking shedding (ADAM17/ADAM10) to Src/FAK, PI3K/AKT, and RhoA/ROCK activation that drives tumor cell migration and invasion.","evidence":"Western blot pathway profiling, kinase inhibitors, neutralizing antibodies, knockdown, and in vivo metastasis models across prostate, lung, and hepatocellular cancer","pmids":["30066854","30628679","32319605","38280480"],"confidence":"Medium","gaps":["Whether autocrine vs. stromal-derived CX3CL1 dominates differs by tumor","EGFR Tyr992 transactivation mechanism not generalized across cancers"]},{"year":2024,"claim":"Positioned CX3CL1 within antitumor immunity, acting as an immunogenic apoptosis 'find me' signal and as an m6A/YTHDF2-stabilized transcript that recruits CD8+ T cells.","evidence":"Recombinant CX3CL1 prophylactic vaccination across cell-death modalities; liver-specific Ythdf2 knockout mice with cGAS-STING and CD8+ recruitment analysis","pmids":["39011040","39237909"],"confidence":"Medium","gaps":["Receptor/cell type sensing the 'find me' signal not pinned down","Direct demonstration that m6A-stabilized CX3CL1 transcript yields functional protein gradient incomplete"]},{"year":null,"claim":"How CX3CL1 cleavage state, oligomerization, and the soluble/membrane/intracellular-domain triad are coordinately regulated to dictate context-specific outcomes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking TM oligomerization to receptor engagement","Transcriptional program of the nuclear ICD not mapped genome-wide","Determinants selecting adhesion vs. chemoattraction vs. back-signaling in a given tissue undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[9,26,29]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[1,5]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[12,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,5,6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,29]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,21,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,12,15,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,15,16,20]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,2]}],"complexes":[],"partners":["CX3CR1","ADAM10","ADAM17"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P78423","full_name":"Fractalkine","aliases":["C-X3-C motif chemokine 1","CX3C membrane-anchored chemokine","Neurotactin","Small-inducible cytokine D1"],"length_aa":397,"mass_kda":42.2,"function":"Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1 (PubMed:12055230, PubMed:21829356, PubMed:23125415, PubMed:9782118, PubMed:9931005). The CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis (PubMed:12055230, PubMed:9024663, PubMed:9177350, PubMed:9782118). Regulates leukocyte adhesion and migration processes at the endothelium (PubMed:9024663, PubMed:9177350). Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner (PubMed:23125415, PubMed:24789099). In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins (PubMed:23125415, PubMed:24789099). In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1 (PubMed:23125415, PubMed:24789099) The soluble form is chemotactic for T-cells and monocytes, but not for neutrophils The membrane-bound form promotes adhesion of those leukocytes to endothelial cells (Microbial infection) Mediates the cytoadherence of erythrocytes infected with parasite P.falciparum (strain 3D7) with endothelial cells by interacting with P.falciparum CBP1 and CBP2 expressed at the surface of erythrocytes (PubMed:27653778). The adhesion prevents the elimination of infected erythrocytes by the spleen (Probable)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P78423/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CX3CL1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CX3CL1","total_profiled":1310},"omim":[{"mim_id":"621526","title":"GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE-LIKE PROTEIN; QPCTL","url":"https://www.omim.org/entry/621526"},{"mim_id":"607884","title":"CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 1; CMTM1","url":"https://www.omim.org/entry/607884"},{"mim_id":"607065","title":"GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE; QPCT","url":"https://www.omim.org/entry/607065"},{"mim_id":"605402","title":"CD274 MOLECULE; CD274","url":"https://www.omim.org/entry/605402"},{"mim_id":"605398","title":"CHEMOKINE, CXC MOTIF, LIGAND 16; CXCL16","url":"https://www.omim.org/entry/605398"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CX3CL1"},"hgnc":{"alias_symbol":["NTN","C3Xkine","ABCD-3","CXC3C","CXC3"],"prev_symbol":["SCYD1"]},"alphafold":{"accession":"P78423","domains":[{"cath_id":"2.40.50.40","chopping":"48-97","consensus_level":"high","plddt":93.1456,"start":48,"end":97}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P78423","model_url":"https://alphafold.ebi.ac.uk/files/AF-P78423-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P78423-F1-predicted_aligned_error_v6.png","plddt_mean":55.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CX3CL1","jax_strain_url":"https://www.jax.org/strain/search?query=CX3CL1"},"sequence":{"accession":"P78423","fasta_url":"https://rest.uniprot.org/uniprotkb/P78423.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P78423/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P78423"}},"corpus_meta":[{"pmid":"29361745","id":"PMC_29361745","title":"Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29361745","citation_count":220,"is_preprint":false},{"pmid":"33065974","id":"PMC_33065974","title":"The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33065974","citation_count":212,"is_preprint":false},{"pmid":"11870871","id":"PMC_11870871","title":"Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.","date":"2002","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/11870871","citation_count":202,"is_preprint":false},{"pmid":"25152714","id":"PMC_25152714","title":"Modulating neurotoxicity through CX3CL1/CX3CR1 signaling.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25152714","citation_count":187,"is_preprint":false},{"pmid":"34492237","id":"PMC_34492237","title":"CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34492237","citation_count":144,"is_preprint":false},{"pmid":"15067194","id":"PMC_15067194","title":"Regulation of CX3CL1/fractalkine expression in endothelial cells.","date":"2004","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/15067194","citation_count":128,"is_preprint":false},{"pmid":"23974513","id":"PMC_23974513","title":"Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway.","date":"2013","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/23974513","citation_count":109,"is_preprint":false},{"pmid":"28125278","id":"PMC_28125278","title":"Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28125278","citation_count":99,"is_preprint":false},{"pmid":"16053521","id":"PMC_16053521","title":"CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin.","date":"2005","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/16053521","citation_count":98,"is_preprint":false},{"pmid":"21126357","id":"PMC_21126357","title":"CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration.","date":"2010","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/21126357","citation_count":95,"is_preprint":false},{"pmid":"32466280","id":"PMC_32466280","title":"Fractalkine/CX3CL1 in Neoplastic Processes.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32466280","citation_count":93,"is_preprint":false},{"pmid":"33391453","id":"PMC_33391453","title":"Regulation and biological functions of the CX3CL1-CX3CR1 axis and its relevance in solid cancer: A mini-review.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33391453","citation_count":87,"is_preprint":false},{"pmid":"32819407","id":"PMC_32819407","title":"MicroRNA-195 prevents hippocampal microglial/macrophage polarization towards the M1 phenotype induced by chronic brain hypoperfusion through regulating CX3CL1/CX3CR1 signaling.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32819407","citation_count":84,"is_preprint":false},{"pmid":"17467666","id":"PMC_17467666","title":"Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17467666","citation_count":82,"is_preprint":false},{"pmid":"20630606","id":"PMC_20630606","title":"Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20630606","citation_count":81,"is_preprint":false},{"pmid":"35914622","id":"PMC_35914622","title":"CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status.","date":"2022","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/35914622","citation_count":76,"is_preprint":false},{"pmid":"30948201","id":"PMC_30948201","title":"CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis.","date":"2019","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/30948201","citation_count":75,"is_preprint":false},{"pmid":"12476352","id":"PMC_12476352","title":"Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.","date":"2002","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/12476352","citation_count":75,"is_preprint":false},{"pmid":"14533779","id":"PMC_14533779","title":"CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis.","date":"2003","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14533779","citation_count":70,"is_preprint":false},{"pmid":"15608300","id":"PMC_15608300","title":"Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.","date":"2005","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15608300","citation_count":69,"is_preprint":false},{"pmid":"20511186","id":"PMC_20511186","title":"CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-β1.","date":"2010","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20511186","citation_count":68,"is_preprint":false},{"pmid":"24799766","id":"PMC_24799766","title":"Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24799766","citation_count":65,"is_preprint":false},{"pmid":"22464888","id":"PMC_22464888","title":"Altered expression of CX3CL1 in patients with epilepsy and in a rat model.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22464888","citation_count":65,"is_preprint":false},{"pmid":"32060841","id":"PMC_32060841","title":"CX3CL1 Signaling in the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060841","citation_count":64,"is_preprint":false},{"pmid":"18367676","id":"PMC_18367676","title":"CX3CL1 and CCL14 regulate extracellular matrix and adhesion molecules in the trophoblast: potential roles in human embryo implantation.","date":"2008","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18367676","citation_count":64,"is_preprint":false},{"pmid":"34163473","id":"PMC_34163473","title":"Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34163473","citation_count":62,"is_preprint":false},{"pmid":"24556958","id":"PMC_24556958","title":"The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis.","date":"2014","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/24556958","citation_count":61,"is_preprint":false},{"pmid":"30066854","id":"PMC_30066854","title":"CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30066854","citation_count":60,"is_preprint":false},{"pmid":"27429982","id":"PMC_27429982","title":"CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.","date":"2016","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/27429982","citation_count":59,"is_preprint":false},{"pmid":"35461837","id":"PMC_35461837","title":"CX3CL1 inhibits NLRP3 inflammasome-induced microglial pyroptosis and improves neuronal function in mice with experimentally-induced ischemic stroke.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35461837","citation_count":56,"is_preprint":false},{"pmid":"27484962","id":"PMC_27484962","title":"Fractalkine/CX3CL1 in rheumatoid arthritis.","date":"2016","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/27484962","citation_count":55,"is_preprint":false},{"pmid":"32445958","id":"PMC_32445958","title":"Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32445958","citation_count":55,"is_preprint":false},{"pmid":"30843484","id":"PMC_30843484","title":"Crosstalk between the CX3CL1/CX3CR1 Axis and Inflammatory Signaling Pathways in Tissue Injury.","date":"2019","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/30843484","citation_count":51,"is_preprint":false},{"pmid":"37626378","id":"PMC_37626378","title":"CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through NF-κB signaling pathway in ankylosing spondylitis in vitro.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37626378","citation_count":51,"is_preprint":false},{"pmid":"32410624","id":"PMC_32410624","title":"Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32410624","citation_count":50,"is_preprint":false},{"pmid":"29259682","id":"PMC_29259682","title":"Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway.","date":"2016","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29259682","citation_count":48,"is_preprint":false},{"pmid":"31036641","id":"PMC_31036641","title":"Soluble CX3CL1 gene therapy improves cone survival and function in mouse models of retinitis pigmentosa.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31036641","citation_count":47,"is_preprint":false},{"pmid":"30628679","id":"PMC_30628679","title":"CX3CL1 promotes lung cancer cell migration and invasion via the Src/focal adhesion kinase signaling pathway.","date":"2019","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30628679","citation_count":46,"is_preprint":false},{"pmid":"29446734","id":"PMC_29446734","title":"CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?","date":"2017","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29446734","citation_count":44,"is_preprint":false},{"pmid":"31744815","id":"PMC_31744815","title":"Tenophages: a novel macrophage-like tendon cell population expressing CX3CL1 and CX3CR1.","date":"2019","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31744815","citation_count":44,"is_preprint":false},{"pmid":"24821910","id":"PMC_24821910","title":"CX₃CL1 (fractalkine) and its receptor CX₃CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24821910","citation_count":43,"is_preprint":false},{"pmid":"34009468","id":"PMC_34009468","title":"Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease.","date":"2021","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/34009468","citation_count":42,"is_preprint":false},{"pmid":"23956503","id":"PMC_23956503","title":"Fractalkine (CX3CL1) and its receptor CX3CR1 may contribute to increased angiogenesis in diabetic placenta.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23956503","citation_count":42,"is_preprint":false},{"pmid":"38731899","id":"PMC_38731899","title":"CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38731899","citation_count":40,"is_preprint":false},{"pmid":"29729150","id":"PMC_29729150","title":"CD200-, CX3CL1-, and TREM2-mediated neuron-microglia interactions and their involvements in Alzheimer's disease.","date":"2018","source":"Reviews in the neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/29729150","citation_count":40,"is_preprint":false},{"pmid":"31822518","id":"PMC_31822518","title":"Activated CX3CL1/Smad2 Signals Prevent Neuronal Loss and Alzheimer's Tau Pathology-Mediated Cognitive Dysfunction.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31822518","citation_count":40,"is_preprint":false},{"pmid":"17616549","id":"PMC_17616549","title":"Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.","date":"2007","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17616549","citation_count":38,"is_preprint":false},{"pmid":"32717023","id":"PMC_32717023","title":"Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interaction.","date":"2021","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/32717023","citation_count":37,"is_preprint":false},{"pmid":"24324211","id":"PMC_24324211","title":"CX3CL1 and CX3CR1 expression in tertiary lymphoid structures in salivary gland infiltrates: fractalkine contribution to lymphoid neogenesis in Sjogren's syndrome.","date":"2013","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24324211","citation_count":37,"is_preprint":false},{"pmid":"39453382","id":"PMC_39453382","title":"Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer's disease.","date":"2024","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/39453382","citation_count":35,"is_preprint":false},{"pmid":"31209068","id":"PMC_31209068","title":"The intracellular domain of CX3CL1 regulates adult neurogenesis and Alzheimer's amyloid pathology.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31209068","citation_count":35,"is_preprint":false},{"pmid":"32319605","id":"PMC_32319605","title":"ADAM17-regulated CX3CL1 expression produced by bone marrow endothelial cells promotes spinal metastasis from hepatocellular carcinoma.","date":"2020","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32319605","citation_count":35,"is_preprint":false},{"pmid":"18436581","id":"PMC_18436581","title":"Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration.","date":"2008","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/18436581","citation_count":34,"is_preprint":false},{"pmid":"33765141","id":"PMC_33765141","title":"CX3CL1-CX3CR1 Signaling Deficiency Exacerbates Obesity-induced Inflammation and Insulin Resistance in Male Mice.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33765141","citation_count":33,"is_preprint":false},{"pmid":"22093090","id":"PMC_22093090","title":"Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death.","date":"2011","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/22093090","citation_count":33,"is_preprint":false},{"pmid":"25503251","id":"PMC_25503251","title":"CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25503251","citation_count":31,"is_preprint":false},{"pmid":"23117657","id":"PMC_23117657","title":"Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II.","date":"2012","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23117657","citation_count":31,"is_preprint":false},{"pmid":"37175935","id":"PMC_37175935","title":"CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer's Disease.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37175935","citation_count":30,"is_preprint":false},{"pmid":"17151328","id":"PMC_17151328","title":"Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells.","date":"2006","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/17151328","citation_count":30,"is_preprint":false},{"pmid":"14698146","id":"PMC_14698146","title":"The chemokine CX3CL1 regulates NK cell activity in vivo.","date":"2003","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14698146","citation_count":30,"is_preprint":false},{"pmid":"31780870","id":"PMC_31780870","title":"Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis.","date":"2019","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31780870","citation_count":29,"is_preprint":false},{"pmid":"32976527","id":"PMC_32976527","title":"CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32976527","citation_count":29,"is_preprint":false},{"pmid":"37875838","id":"PMC_37875838","title":"Targeted inhibition of CX3CL1 limits podocytes ferroptosis to ameliorate cisplatin-induced acute kidney injury.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37875838","citation_count":28,"is_preprint":false},{"pmid":"39237909","id":"PMC_39237909","title":"YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39237909","citation_count":28,"is_preprint":false},{"pmid":"35770395","id":"PMC_35770395","title":"Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer.","date":"2022","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35770395","citation_count":28,"is_preprint":false},{"pmid":"30553772","id":"PMC_30553772","title":"CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.","date":"2018","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30553772","citation_count":28,"is_preprint":false},{"pmid":"18296082","id":"PMC_18296082","title":"Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.","date":"2008","source":"European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18296082","citation_count":28,"is_preprint":false},{"pmid":"23470165","id":"PMC_23470165","title":"Interaction between CX3CL1 and CX3CR1 regulates vasculitis induced by immune complex deposition.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23470165","citation_count":28,"is_preprint":false},{"pmid":"37175729","id":"PMC_37175729","title":"The Cytokine CX3CL1 and ADAMs/MMPs in Concerted Cross-Talk Influencing Neurodegenerative Diseases.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37175729","citation_count":26,"is_preprint":false},{"pmid":"27156946","id":"PMC_27156946","title":"Expression of Chemokine XCL2 and CX3CL1 in Lung Cancer.","date":"2016","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/27156946","citation_count":26,"is_preprint":false},{"pmid":"28522896","id":"PMC_28522896","title":"Shear Stress Counteracts Endothelial CX3CL1 Induction and Monocytic Cell Adhesion.","date":"2017","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/28522896","citation_count":26,"is_preprint":false},{"pmid":"25845619","id":"PMC_25845619","title":"Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability.","date":"2015","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/25845619","citation_count":26,"is_preprint":false},{"pmid":"12727021","id":"PMC_12727021","title":"Human keratinocytes express fractalkine/CX3CL1.","date":"2003","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/12727021","citation_count":26,"is_preprint":false},{"pmid":"18538418","id":"PMC_18538418","title":"Glial cross-talk by transmembrane chemokines CX3CL1 and CXCL16.","date":"2008","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/18538418","citation_count":26,"is_preprint":false},{"pmid":"23147224","id":"PMC_23147224","title":"ERK pathway and sheddases play an essential role in ethanol-induced CX3CL1 release in pancreatic stellate cells.","date":"2012","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23147224","citation_count":26,"is_preprint":false},{"pmid":"32799418","id":"PMC_32799418","title":"Platelets are recruited to hepatocellular carcinoma tissues in a CX3CL1-CX3CR1 dependent manner and induce tumour cell apoptosis.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32799418","citation_count":26,"is_preprint":false},{"pmid":"31625434","id":"PMC_31625434","title":"Endothelial expression of fractalkine (CX3CL1) is induced by Toll-like receptor 3 signaling in cultured human glomerular endothelial cells.","date":"2019","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31625434","citation_count":24,"is_preprint":false},{"pmid":"26745855","id":"PMC_26745855","title":"The role of CX3CL1 in fetal-maternal interaction during human gestation.","date":"2016","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/26745855","citation_count":24,"is_preprint":false},{"pmid":"33641164","id":"PMC_33641164","title":"Potential biomarkers reflecting inflammation in patients with severe periodontitis: Fractalkine (CX3CL1) and its receptor (CX3CR1).","date":"2021","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/33641164","citation_count":24,"is_preprint":false},{"pmid":"17002687","id":"PMC_17002687","title":"The CX3CL1-CX3CR1 system and psoriasis.","date":"2006","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17002687","citation_count":24,"is_preprint":false},{"pmid":"38280480","id":"PMC_38280480","title":"Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4/ADAM10/CX3CL1 axis.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38280480","citation_count":23,"is_preprint":false},{"pmid":"37928902","id":"PMC_37928902","title":"Pathophysiological impact of CXC and CX3CL1 chemokines in preeclampsia and gestational diabetes mellitus.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37928902","citation_count":23,"is_preprint":false},{"pmid":"30606080","id":"PMC_30606080","title":"Regulation of CX3CL1 Expression in Human First-Trimester Decidual Cells: Implications for Preeclampsia.","date":"2019","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/30606080","citation_count":23,"is_preprint":false},{"pmid":"36397015","id":"PMC_36397015","title":"CX3CL1 promotes cell sensitivity to ferroptosis and is associated with the tumor microenvironment in clear cell renal cell carcinoma.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36397015","citation_count":23,"is_preprint":false},{"pmid":"22692452","id":"PMC_22692452","title":"CX3CL1 expression in the conjunctiva is involved in immune cell trafficking during toxic ocular surface inflammation.","date":"2012","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22692452","citation_count":23,"is_preprint":false},{"pmid":"30717334","id":"PMC_30717334","title":"Placental CX3CL1 is Deregulated by Angiotensin II and Contributes to a Pro-Inflammatory Trophoblast-Monocyte Interaction.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30717334","citation_count":22,"is_preprint":false},{"pmid":"14605272","id":"PMC_14605272","title":"Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thy1 glomerulonephritis in rats.","date":"2003","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/14605272","citation_count":22,"is_preprint":false},{"pmid":"29356931","id":"PMC_29356931","title":"CX3CL1/CX3CR1 Axis Contributes to Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation and Inflammatory Cytokine Production.","date":"2018","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29356931","citation_count":21,"is_preprint":false},{"pmid":"28848146","id":"PMC_28848146","title":"Naringin Protects Against High Glucose-Induced Human Endothelial Cell Injury Via Antioxidation and CX3CL1 Downregulation.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28848146","citation_count":21,"is_preprint":false},{"pmid":"32494000","id":"PMC_32494000","title":"CX3CL1 homo-oligomerization drives cell-to-cell adherence.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32494000","citation_count":20,"is_preprint":false},{"pmid":"23229614","id":"PMC_23229614","title":"The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas.","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23229614","citation_count":20,"is_preprint":false},{"pmid":"38660801","id":"PMC_38660801","title":"Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling.","date":"2024","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38660801","citation_count":19,"is_preprint":false},{"pmid":"38287522","id":"PMC_38287522","title":"PVT1 promotes proliferation and macrophage immunosuppressive polarization through STAT1 and CX3CL1 regulation in glioblastoma multiforme.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38287522","citation_count":18,"is_preprint":false},{"pmid":"31704270","id":"PMC_31704270","title":"Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1β.","date":"2019","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31704270","citation_count":18,"is_preprint":false},{"pmid":"22457367","id":"PMC_22457367","title":"CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22457367","citation_count":17,"is_preprint":false},{"pmid":"35370759","id":"PMC_35370759","title":"CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35370759","citation_count":17,"is_preprint":false},{"pmid":"33710617","id":"PMC_33710617","title":"Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33710617","citation_count":17,"is_preprint":false},{"pmid":"27923568","id":"PMC_27923568","title":"Noradrenaline induces CX3CL1 production and release by neurons.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27923568","citation_count":16,"is_preprint":false},{"pmid":"33456354","id":"PMC_33456354","title":"STAT3/miR-15a-5p/CX3CL1 Loop Regulates Proliferation and Migration of Vascular Endothelial Cells in Atherosclerosis.","date":"2021","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33456354","citation_count":16,"is_preprint":false},{"pmid":"39011040","id":"PMC_39011040","title":"CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39011040","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54918,"output_tokens":8804,"usd":0.148407,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18758,"output_tokens":3839,"usd":0.094882,"stage2_stop_reason":"end_turn"},"total_usd":0.243289,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"CX3CL1 is sequentially processed by alpha-secretase (ADAM10) and then gamma-secretase, generating C-terminal fragments (CTFs). ADAM10-mediated ectodomain shedding at multiple cleavage sites releases the soluble chemokine domain, and inhibitor studies plus presenilin 1/2-deficient cell lines established gamma-secretase (but not beta-secretase) involvement in processing the remaining CTF, analogous to Notch/E-cadherin processing.\",\n      \"method\": \"Inhibitor studies, presenilin 1/2 knockout cell lines, CX3CL1 constructs C-terminally fused to 2Z-tag for CTF detection, Western blotting\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal approaches (genetic knockout cells, pharmacological inhibitors, tagged constructs) in a single rigorous mechanistic study\",\n      \"pmids\": [\"17467666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CX3CL1 forms homo-oligomers of 3–7 monomers driven by its transmembrane domain. The transmembrane peptide self-associates in both cellular and acellular lipid environments (while a scrambled version does not), and a transmembrane peptide inhibitor blocks both CX3CL1 oligomerization and its adhesive function, demonstrating that oligomerization is required for cell-to-cell adhesion.\",\n      \"method\": \"Native electrophoresis, single-molecule fluorescence kinetics, FRAP assays with transmembrane peptides in cells and liposomes, molecular modeling, adhesion inhibition assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal biophysical methods in a single study demonstrating structure-function relationship\",\n      \"pmids\": [\"32494000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The CX3CL1 intracellular domain (CX3CL1-ICD), released by sequential α-, β-, and γ-secretase cleavage, translocates to the cell nucleus and alters gene expression (back-signaling). Overexpression of the CX3CL1 C-terminal fragment in 5xFAD Alzheimer mice reduced amyloid deposition and neuronal loss; this effect was attributed to enhanced neurogenesis through activation of the TGFβ2/3-Smad2/3 pathway and was independent of CX3CR1 binding.\",\n      \"method\": \"Transgenic mouse overexpression, morphological and unbiased RNA-sequencing analyses, immunofluorescence, genetic epistasis in 5xFAD model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with RNA-seq pathway validation, single lab\",\n      \"pmids\": [\"31209068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CL1 overexpression in neurons (Tg-CX3CL1 mice) enhances adult neurogenesis in subgranular and subventricular zones via upregulation of TGF-β2 and TGF-β3 and activation of downstream Smad2 signaling. Neuronal deletion of Smad2 mitigated CX3CL1-enhanced neurogenesis, placing CX3CL1 upstream of TGF-β2/3-Smad2 in the neurogenesis pathway.\",\n      \"method\": \"Transgenic mouse overexpression, Smad2 conditional knockout, crossing with PS19 tau mice, behavioral testing, genetic epistasis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with multiple transgenic crosses and behavioral readouts, single lab\",\n      \"pmids\": [\"31822518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Soluble CX3CL1 (sFKN) and membrane-bound CX3CL1 (mFKN) exhibit differential activities in vivo: AAV-delivered sFKN fully rescued hippocampal neurogenesis, long-term potentiation, and both long-term and spatial memory deficits in CX3CL1-knockout mice, whereas mFKN only partially restored spatial learning and did not rescue long-term memory or neurogenesis.\",\n      \"method\": \"CX3CL1 knockout mice, AAV gene delivery of two CX3CL1 isoforms, behavioral cognitive testing, hippocampal neurogenesis assays, LTP electrophysiology\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with isoform-specific rescue, multiple functional readouts, single lab\",\n      \"pmids\": [\"32410624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In polarized renal tubular epithelial cells (MDCK), CX3CL1 is targeted to and immobilized at the apical membrane. Apical targeting depends on N-linked glycosylation but not on the intracellular domain, lipid raft association, O-glycosylation, or direct actin cytoskeleton association (FRAP and fractionation showed membrane immobility but triton-soluble partitioning). Apically localized CX3CL1 enhanced CX3CR1-expressing leukocyte adhesion to the luminal surface.\",\n      \"method\": \"MDCK cell polarization, GFP-tagged CX3CL1, FRAP, cholesterol depletion, N-glycosylation inhibition, triton fractionation, leukocyte adhesion assays\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (FRAP, fractionation, glycosylation mutants, functional adhesion assay) in single study\",\n      \"pmids\": [\"17151328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Thrombin induces endothelial CX3CL1 expression via protease-activated receptor 1 (PAR1) activation and downstream NF-κB signaling. Membrane-anchored CX3CL1 induced on HUVEC by thrombin triggers monocyte adhesion and enhanced CCL2/MCP-1 release by monocytes, potentiating transendothelial migration. The effect was blocked by NF-κB inhibitors and a PAR1 antagonist.\",\n      \"method\": \"RT-PCR, Western blot, flow cytometry, EMSA, ELISA, PAR1 agonist peptide, PAR1 antagonist SCH79797, IκB kinase inhibitor, dominant-negative IκBα overexpression, co-culture adhesion and migration assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal mechanistic approaches (genetic overexpression, pharmacological inhibition, signaling readouts, functional assays) in a single study\",\n      \"pmids\": [\"18436581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ERK pathway activation and ADAM17 (and MMPs) are required for ethanol-induced CX3CL1 shedding/release from pancreatic stellate cells. Ethanol and phorbol ester synergistically increase CX3CL1 release via ERK and ADAM17 activation; specific inhibitors of ERK, MMP, and ADAM each suppressed CX3CL1 release.\",\n      \"method\": \"Primary rat pancreatic stellate cell culture, real-time RT-PCR, Western blot, ELISA, ERK/MMP/ADAM pharmacological inhibitors\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitor dissection with multiple targets, single lab\",\n      \"pmids\": [\"23147224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CX3CL1 treatment of trophoblast cells (AC1M-88) increases adhesion to fibronectin and regulates expression of more than 30 ECM/adhesion genes including α-catenin (CTNNA1), osteopontin (SPP1), integrin α6 (ITGA6), MMP12, integrin β5 (ITGB5), and ECM1, demonstrating that CX3CL1 promotes trophoblast migration by altering adhesion molecule and ECM profiles.\",\n      \"method\": \"Pathway-specific oligoarrays, quantitative real-time RT-PCR, fibronectin adhesion assay, immunohistochemistry of first-trimester implantation sites\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene expression arrays validated by qPCR and functional adhesion assay, single lab\",\n      \"pmids\": [\"18367676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CX3CL1 regulates NK cell activity in vivo: blocking anti-CX3CL1 or anti-CX3CR1 antibodies reduced NK-mediated clearance of YAC-1 tumor cells by 4–5 fold in mice. NK cell binding to activated endothelial monolayers was significantly inhibited by anti-CX3CR1 antibody or soluble CX3CL1. No direct effect on in vitro NK cytolytic activity was detected, indicating the effect operates through adhesion/trafficking rather than direct cytotoxicity.\",\n      \"method\": \"In vivo radiolabeled tumor cell clearance model, anti-CX3CL1/CX3CR1 antibody blocking, in vitro NK cytolysis assay, endothelial adhesion assay\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo blocking experiments with multiple antibodies and functional readouts, single lab\",\n      \"pmids\": [\"14698146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CX3CR1 expression by both Th2 and Th1 CD4+ T cells is required for atopic dermatitis (AD) pathology. CX3CR1 deficiency or CX3CL1 blockade profoundly reduced AD but not psoriasis. Adoptive transfer experiments established that CX3CR1 controls CD4+ T cell retention in inflamed skin (not antigen presentation or T cell proliferation), identifying a novel function for this chemokine receptor distinct from its role in asthma where it regulates T cell survival.\",\n      \"method\": \"CX3CR1-deficient mice, CX3CL1 blocking antibody, adoptive transfer of CX3CR1-deficient T cells, murine AD and psoriasis models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO + adoptive transfer) with disease-specific phenotypic readouts; mechanism (retention vs. survival/proliferation) dissected by orthogonal experiments\",\n      \"pmids\": [\"24821910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Exogenous CX3CL1 (fractalkine) protects striatal neurons from synergistic morphine + HIV-1 Tat-induced dendritic loss and death through CX3CR1 on microglia: antibody blockade of CX3CR1 mimicked the toxicity, and CX3CL1 failed to protect neurons co-cultured with CX3CR1-null glia, demonstrating that neuroprotection requires glial CX3CR1. CX3CL1 also normalized elevated microglial motility caused by Tat/morphine.\",\n      \"method\": \"Wild-type and Cx3cr1 knockout mouse co-cultures, time-lapse digital microscopy, antibody blockade, ELISA, immunofluorescence, Western blot\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (CX3CR1 KO glia) combined with pharmacological rescue and time-lapse tracking, single lab\",\n      \"pmids\": [\"22093090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CX3CL1 activates the Src/FAK signaling pathway in prostate cancer cells through the Tyr992 residue of EGFR phosphorylation, promoting cell proliferation, migration, invasion and inhibiting apoptosis; kinase inhibitors of Src and FAK blocked CX3CL1-induced migration, and CX3CR1 overexpression promoted spinal metastasis in an in vivo mouse model.\",\n      \"method\": \"Western blot for Src/FAK phosphorylation, siRNA knockdown, kinase inhibitors, Transwell migration/invasion assays, in vivo mouse spinal metastasis model\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway activation by Western blot + inhibitor rescue + in vivo validation, single lab\",\n      \"pmids\": [\"30066854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CL1 promotes lung cancer cell (H460) migration and invasion via time-dependent activation of the Src/FAK signaling pathway; blocking Src with saracatinib prevented CX3CL1-mediated migration and invasion without affecting proliferation.\",\n      \"method\": \"Western blot for Src/FAK phosphorylation time-course, Transwell migration/invasion assays, saracatinib pharmacological inhibition\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase pathway activation confirmed by Western blot with pharmacological rescue, single lab\",\n      \"pmids\": [\"30628679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Endogenous CX3CL1 negatively regulates glioma cell invasion by promoting tumor cell aggregation; neutralizing anti-CX3CL1 antibody delayed tumor aggregation and increased invasiveness. TGF-β1 decreases CX3CL1 mRNA and protein expression in glioma cells (confirmed by both recombinant TGF-β1 treatment and TGF-β1 siRNA knockdown), suggesting TGF-β1-mediated reduction of CX3CL1 contributes to glioma invasiveness.\",\n      \"method\": \"Neutralizing anti-CX3CL1 monoclonal antibody, recombinant TGF-β1 treatment, siRNA knockdown of TGF-β1, RT-PCR, Western blot, cell adhesion and invasion assays\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional antibody neutralization + siRNA genetic manipulation, single lab\",\n      \"pmids\": [\"20511186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAM17-activated by MAPK14 (p38) in bone marrow endothelial cells (BMECs) mediates CX3CL1 shedding and release of soluble CX3CL1, which then promotes migration and invasion of hepatocellular carcinoma cells; neutralization of CX3CL1 inhibited BMEC-enhanced tumor cell migration. CX3CL1 activates the Src/PTK2 signaling axis and downstream PIK3CA/AKT and RHOA/ROCK2 pathways in HCC cells.\",\n      \"method\": \"Neutralizing antibody, Western blot for signaling pathway activation, Transwell assays, MAPK14 activation studies, in vivo mouse spinal metastasis model with CX3CR1 overexpression\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway readouts with neutralization rescue and in vivo validation, single lab\",\n      \"pmids\": [\"32319605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Platelet-derived TLR4/NF-κB signaling increases ADAM10 expression in HCC tumor cells; ADAM10 then catalyzes CX3CL1 shedding, and the released CX3CL1 binds CX3CR1 to induce epithelial-mesenchymal transition and activate RhoA signaling, promoting tumor cell migration, invasion, and endothelial permeability. TLR4 knockdown or ADAM10 inhibition blocked platelet-enhanced tumor metastasis in vivo.\",\n      \"method\": \"TLR4 siRNA knockdown, ADAM10 inhibition, Western blot, Transwell migration/invasion assays, endothelial permeability assay, in vivo mouse lung metastasis model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown + pharmacological inhibition + in vivo validation, single lab\",\n      \"pmids\": [\"38280480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Angiotensin II induces functional CX3CL1 expression in arterial (but not venous) endothelial cells through TNF-α and Nox5/ERK1/2/p38 MAPK/NF-κB signaling, leading to mononuclear cell adhesion. Knockdown of TNF-α or Nox5 with siRNA, or pharmacological inhibition of ERK1/2, p38, or NF-κB, abolished Ang-II-induced CX3CL1 upregulation and monocyte arrest. CX3CR1-deficient mice showed 83% reduction in arteriolar leukocyte adhesion.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibitors (ERK1/2, p38, NF-κB), in vivo CX3CR1-deficient mice, human umbilical arterial vs. venous endothelial cells, mononuclear cell adhesion assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (siRNA, KO mice) and pharmacological dissection with multiple pathway targets and functional adhesion readout, arterial vs. venous specificity established\",\n      \"pmids\": [\"23117657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In glomerulonephritis, activated mesangial cells are a major source of upregulated CX3CL1; TNF-α, IL-1β, PDGF-AB, and bFGF all upregulate CX3CL1 mRNA and protein in cultured mesangial cells. This cytokine/growth factor-stimulated expression is abolished by NF-κB inhibitors (curcumin, MG132), establishing NF-κB as the required transcriptional mediator.\",\n      \"method\": \"Northern blot, Western blot, RT-PCR, in situ hybridization combined with immunohistochemistry, NF-κB inhibitors (curcumin, MG132), rat anti-Thy1 glomerulonephritis model\",\n      \"journal\": \"Nephrology, dialysis, transplantation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro NF-κB inhibitor studies validated in vivo by ISH/IHC cell-type identification, single lab\",\n      \"pmids\": [\"14605272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AAV8-delivered soluble CX3CL1 (sCX3CL1) significantly prolongs cone photoreceptor survival and improves visual function in three RP mouse strains. Pharmacological depletion of ~99% of microglia failed to abrogate the cone-rescue effect, demonstrating that sCX3CL1 acts via a pathway that does not require normal microglial numbers.\",\n      \"method\": \"AAV8 subretinal injection, three RP mouse strains, pharmacological microglia depletion, RNA sequencing of microglia, visual function testing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, pharmacological epistasis, transcriptomics in a single comprehensive study\",\n      \"pmids\": [\"31036641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CX3CL1 directly induces platelet migration in vitro; CX3CR1/Syk/PI3K pathway components are essential for CX3CL1-induced platelet migration. Hypoxia enhances platelet migration by upregulating CX3CL1 expression in HCC cells. CX3CL1 knockdown in HCC cells reduced platelet infiltration both in vitro and in an orthotopic HCC mouse model.\",\n      \"method\": \"Platelet migration assay, CX3CR1/Syk/PI3K inhibitors, CX3CL1 knockdown, hypoxia treatment, orthotopic HCC mouse model\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection + genetic knockdown + in vivo validation, single lab\",\n      \"pmids\": [\"32799418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"YTHDF2 (an m6A reader) in peritumoral hepatocytes stabilizes CX3CL1 transcripts in an m6A-dependent manner, increasing CX3CL1 expression and CD8+ T cell recruitment to suppress liver tumor growth. Oxaliplatin upregulates YTHDF2 expression via the cGAS-STING pathway, linking chemotherapy-induced innate immune signaling to CX3CL1-mediated adaptive immune responses.\",\n      \"method\": \"Liver-specific Ythdf2 knockout mice, tumor-bearing mouse models, m6A-dependent mRNA stability assays, cGAS-STING pathway analysis, CD8+ T cell recruitment quantification\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with mechanistic pathway (m6A/YTHDF2/CX3CL1) and functional immune readout, single lab\",\n      \"pmids\": [\"39237909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Neuronal cathepsin S (CTSS) overexpression activates the CX3CL1-CX3CR1 axis (and JAK2-STAT3 pathway) to drive microglial activation toward M1 pro-inflammatory phenotype, worsening brain inflammation in aging and AD. The selective CTSS inhibitor LY3000328 rescued AD-related pathological features in APP/PS1 mice. CTSS was further shown to alter cathepsin B and L activities in microglia.\",\n      \"method\": \"CTSS overexpression in neurons, FACS, transcriptome (RNA-seq), CTSS inhibitor LY3000328, APP/PS1 mouse model, immunofluorescence\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic overexpression + pharmacological inhibition + transcriptomic pathway validation in vivo, single lab\",\n      \"pmids\": [\"39453382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CX3CR1-CX3CL1 interaction in peritoneal fibrosis: CX3CL1 on peritoneal mesothelial cells interacts with CX3CR1-expressing macrophages in a positive feedback loop—macrophage cytokines (IL-1β) promote mesothelial CX3CL1 and TGF-β expression; TGF-β in turn upregulates CX3CR1 in monocytic cells. CX3CR1 deficiency or deletion protected against dialysate-induced peritoneal fibrosis in mouse models.\",\n      \"method\": \"CX3CR1-deficient mice, peritoneal dialysis mouse model, bone marrow transplantation, in vitro cytokine stimulation of mesothelial/monocytic cells, Western blot\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO + bone marrow transplant + in vitro mechanistic dissection, single lab\",\n      \"pmids\": [\"30948201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CX3CL1 inhibition in cisplatin-induced acute kidney injury reduces podocyte ferroptosis by attenuating intracellular iron overload, lipid peroxidation (MDA, ROS), and mitochondrial dysfunction, while preserving GPX4 and XCT activity. CX3CL1 inhibition also attenuated endoplasmic reticulum stress (GRP78/eIF2α/CHOP pathway) and HIF-1α/HO-1 expression in podocytes in vitro and in vivo.\",\n      \"method\": \"CX3CL1 knockout mice, cisplatin model, RNA-seq, Western blot, immunofluorescence, in vitro podocyte cisplatin treatment, transmission electron microscopy for mitochondria\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout + in vitro mechanistic studies + RNA-seq pathway analysis, single lab\",\n      \"pmids\": [\"37875838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Noradrenaline induces CX3CL1 protein and mRNA accumulation in primary cortical neurons and increases soluble CX3CL1 levels independent of ADAM10/ADAM17 activity. Noradrenaline-treated neurons showed enhanced dendritic arborization with CX3CL1 accumulating at dendritic bifurcations. The soluble CX3CL1 produced reduced nitrite accumulation in microglia, demonstrating a noradrenaline→neuronal CX3CL1→microglial anti-inflammatory signaling pathway.\",\n      \"method\": \"Primary cortical neuron cultures, ADAM10/ADAM17 inhibitors, RT-PCR, Western blot, ELISA for soluble CX3CL1, nitrite accumulation assay in microglia, immunofluorescence for dendritic morphology\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitor dissection + functional neuron-microglia co-culture readout, single lab\",\n      \"pmids\": [\"27923568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IFN-γ and IL-1β or TNF-α synergistically upregulate CX3CL1 expression in first-trimester decidual cells via MEK1/2, JNK, and NF-κB signaling pathways; specific inhibitors of each pathway suppressed CX3CL1 production. CX3CL1 elicited concentration-dependent enhancement of CD56brightCD16- NK cell migration in chemotaxis assays.\",\n      \"method\": \"Primary human first-trimester decidual cell cultures, cytokine stimulation, MEK1/2/JNK/NF-κB pharmacological inhibitors, ELISA, qRT-PCR, NK cell chemotaxis assay\",\n      \"journal\": \"Reproductive sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling inhibitors in primary human cells + functional chemotaxis assay, single lab\",\n      \"pmids\": [\"30606080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through the NF-κB signaling pathway in ankylosing spondylitis; NF-κB inhibitor BAY-117082 prevented M1 polarization and osteoclast differentiation, and anti-CX3CL1 monoclonal antibody alleviated disease in AS model mice.\",\n      \"method\": \"In vitro macrophage polarization assays, osteoclast differentiation assays, NF-κB inhibitor, anti-CX3CL1 neutralizing antibody, AS mouse model, histological assessment\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibition + antibody blockade + in vivo model, single lab\",\n      \"pmids\": [\"37626378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CX3CL1-CX3CR1 signaling deficiency (Cx3cr1 knockout or Cx3cl1 knockdown) exacerbates obesity-induced adipose tissue inflammation and insulin resistance by reducing M2-polarized macrophage migration and causing M1-dominant shift in epididymal white adipose tissue. Bone marrow transplantation from Cx3cr1-/- donors was sufficient to impair glucose tolerance and insulin sensitivity; in vivo Cx3cl1 administration attenuated glucose intolerance.\",\n      \"method\": \"Cx3cr1 knockout mice, bone marrow transplantation, high-fat diet and leptin-deficient mouse models, flow cytometry, glucose tolerance and insulin tolerance tests\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO + bone marrow transplant establishes cell-autonomous mechanism, multiple models, single lab\",\n      \"pmids\": [\"33765141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CX3CL1 release is specifically associated with immunogenic apoptosis (induced by mitoxantrone) but not ferroptosis or accidental necrosis. Addition of recombinant CX3CL1 to non-immunogenic apoptotic cancer cells in a prophylactic tumor vaccination model induced a robust anti-tumor immune response and improved mouse survival, demonstrating that CX3CL1 functions as a 'find me' signal enhancing immunogenicity of apoptosis.\",\n      \"method\": \"Luminex multiplex cytokine quantification, murine fibrosarcoma and melanoma cell lines, prophylactic vaccination mouse tumor model, comparison across death modalities\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue in vivo with recombinant protein + multi-modal cell death comparison, single lab\",\n      \"pmids\": [\"39011040\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CX3CL1 (fractalkine) is a membrane-anchored transmembrane chemokine that undergoes sequential proteolytic processing—first by ADAM10/ADAM17 alpha-secretase activity to shed a soluble chemokine domain, then by gamma-secretase to release an intracellular domain (ICD) that translocates to the nucleus to regulate gene expression (including TGFβ2/3-Smad2-dependent neurogenesis); its transmembrane domain drives homo-oligomerization (3–7 monomers) that is required for its adhesion function; membrane-bound CX3CL1 mediates firm leukocyte adhesion to endothelium and promotes NK cell trafficking in vivo, while the soluble form acts as a chemoattractant for CX3CR1-expressing monocytes, T cells, NK cells, microglia, and platelets; CX3CL1 signals through the G-protein-coupled receptor CX3CR1 to activate Src/FAK, NF-κB, ERK, PI3K/AKT, and RhoA/ROCK pathways in diverse cellular contexts including cancer invasion, macrophage polarization (M1/M2), osteoclastogenesis, and microglial regulation; its expression in endothelial cells is induced by TNF-α, IL-1β, thrombin (via PAR1/NF-κB), angiotensin II (via Nox5/ERK/p38/NF-κB), and TLR3 signaling, while physiological shear stress suppresses this induction; in neurons, noradrenaline upregulates CX3CL1 independently of ADAM10/17, and CTSS-driven CX3CL1-CX3CR1 axis activation shifts microglia to a pro-inflammatory M1 state; in vivo, soluble CX3CL1 rescues cognitive deficits, hippocampal neurogenesis, and LTP in CX3CL1-knockout mice more effectively than membrane-bound CX3CL1, and AAV-delivered sCX3CL1 protects cone photoreceptors in retinitis pigmentosa via a microglia-independent mechanism.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CX3CL1 (fractalkine) is a membrane-anchored transmembrane chemokine that functions both as a cell-surface adhesion molecule and, after proteolytic release, as a soluble chemoattractant, thereby coupling vascular leukocyte recruitment to chemokine signaling across immune, neural, and tumor contexts [#0, #9]. Its activity is governed by regulated intramembrane proteolysis: ADAM10/ADAM17 alpha-secretase activity sheds the soluble chemokine domain, and gamma-secretase (presenilin-dependent, beta-secretase-independent) then cleaves the remaining C-terminal fragment to liberate an intracellular domain that translocates to the nucleus and reprograms gene expression [#0, #2]. Self-association of its transmembrane domain drives homo-oligomerization (3\\u20137 monomers), which is required for cell-to-cell adhesion, while apical membrane targeting in polarized epithelium depends on N-glycosylation and supports luminal leukocyte capture [#1, #5]. The soluble and membrane-bound forms are functionally distinct in vivo: soluble CX3CL1 more fully restores hippocampal neurogenesis, LTP, and memory in knockout mice, and its nuclear C-terminal fragment promotes adult neurogenesis through a CX3CR1-independent TGF\\u03b22/3\\u2013Smad2 axis [#2, #3, #4]. Through its receptor CX3CR1, CX3CL1 activates Src/FAK, PI3K/AKT, and RhoA/ROCK signaling to drive cancer cell migration, invasion, and metastasis, and it directs leukocyte and platelet trafficking, M1/M2 macrophage polarization, osteoclastogenesis, and microglial phenotype [#12, #15, #20, #27]. Its endothelial and stromal expression is transcriptionally induced through NF-\\u03baB by pro-inflammatory and vasoactive stimuli including TNF-\\u03b1, IL-1\\u03b2, thrombin (via PAR1), and angiotensin II (via Nox5/ERK/p38), positioning CX3CL1 as a convergent effector of inflammatory and metastatic signaling [#6, #17, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established that CX3CL1 governs NK cell function through adhesion and trafficking rather than direct cytotoxicity, defining its core role as a vascular capture molecule.\",\n      \"evidence\": \"In vivo radiolabeled tumor clearance with anti-CX3CL1/CX3CR1 blockade plus endothelial adhesion and NK cytolysis assays in mice\",\n      \"pmids\": [\"14698146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve the soluble vs. membrane-bound contribution to NK adhesion\", \"No molecular signaling pathway dissected\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed how CX3CL1 is spatially positioned for leukocyte capture by defining the determinants of its polarized apical targeting in epithelium.\",\n      \"evidence\": \"GFP-tagged CX3CL1 in polarized MDCK cells with FRAP, glycosylation inhibition, fractionation, and leukocyte adhesion assays\",\n      \"pmids\": [\"17151328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The trafficking machinery reading the N-glycan signal was not identified\", \"Generalizability beyond renal epithelium untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the proteolytic logic of CX3CL1 by demonstrating sequential ADAM10/gamma-secretase processing analogous to Notch, establishing regulated intramembrane proteolysis as the switch between membrane and soluble forms.\",\n      \"evidence\": \"Presenilin 1/2 knockout cells, secretase inhibitors, and tagged CTF-detection constructs with Western blotting\",\n      \"pmids\": [\"17467666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fate and function of the released intracellular fragment not addressed here\", \"Physiological triggers of cleavage in vivo not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected inflammatory protease signaling to CX3CL1 induction by showing thrombin/PAR1/NF-\\u03baB drives endothelial CX3CL1 and downstream monocyte adhesion.\",\n      \"evidence\": \"HUVEC stimulation with PAR1 agonist/antagonist, NF-\\u03baB inhibitors, dominant-negative I\\u03baB\\u03b1, EMSA, and co-culture adhesion/migration assays\",\n      \"pmids\": [\"18436581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to thrombotic inflammation not tested\", \"Did not separate soluble from membrane CX3CL1 contributions\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Generalized NF-\\u03baB-dependent CX3CL1 induction to vasoactive signaling, with angiotensin II acting via TNF-\\u03b1 and Nox5/ERK/p38 in arterial but not venous endothelium.\",\n      \"evidence\": \"siRNA knockdown, pathway inhibitors, arterial vs. venous endothelial cells, and CX3CR1-deficient mice with adhesion readouts\",\n      \"pmids\": [\"23117657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Basis of arterial-venous selectivity not molecularly defined\", \"Link to atherosclerotic disease progression not directly tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed CX3CL1 back-signaling, showing the nuclear-translocating intracellular domain reduces Alzheimer pathology by enhancing neurogenesis through a receptor-independent TGF\\u03b22/3\\u2013Smad2 axis.\",\n      \"evidence\": \"Transgenic CX3CL1-CTF overexpression in 5xFAD mice with RNA-seq, plus Tg-CX3CL1 mice crossed to Smad2 conditional knockouts and tau models\",\n      \"pmids\": [\"31209068\", \"31822518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA-binding or transcriptional targets of the ICD not identified\", \"How nuclear ICD activates TGF\\u03b22/3 transcription is unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that transmembrane-driven homo-oligomerization is mechanistically required for CX3CL1 adhesion, and that soluble and membrane forms are functionally non-equivalent in vivo.\",\n      \"evidence\": \"Biophysical TM-peptide self-association (native gels, single-molecule kinetics, FRAP) and adhesion inhibition; AAV isoform-specific rescue in CX3CL1-knockout mice with LTP/behavioral readouts\",\n      \"pmids\": [\"32494000\", \"32410624\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the oligomer interface not resolved\", \"Mechanism behind superior soluble-form rescue of memory not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established CX3CL1/CX3CR1 as a pro-metastatic axis, linking shedding (ADAM17/ADAM10) to Src/FAK, PI3K/AKT, and RhoA/ROCK activation that drives tumor cell migration and invasion.\",\n      \"evidence\": \"Western blot pathway profiling, kinase inhibitors, neutralizing antibodies, knockdown, and in vivo metastasis models across prostate, lung, and hepatocellular cancer\",\n      \"pmids\": [\"30066854\", \"30628679\", \"32319605\", \"38280480\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether autocrine vs. stromal-derived CX3CL1 dominates differs by tumor\", \"EGFR Tyr992 transactivation mechanism not generalized across cancers\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Positioned CX3CL1 within antitumor immunity, acting as an immunogenic apoptosis 'find me' signal and as an m6A/YTHDF2-stabilized transcript that recruits CD8+ T cells.\",\n      \"evidence\": \"Recombinant CX3CL1 prophylactic vaccination across cell-death modalities; liver-specific Ythdf2 knockout mice with cGAS-STING and CD8+ recruitment analysis\",\n      \"pmids\": [\"39011040\", \"39237909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/cell type sensing the 'find me' signal not pinned down\", \"Direct demonstration that m6A-stabilized CX3CL1 transcript yields functional protein gradient incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CX3CL1 cleavage state, oligomerization, and the soluble/membrane/intracellular-domain triad are coordinately regulated to dictate context-specific outcomes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking TM oligomerization to receptor engagement\", \"Transcriptional program of the nuclear ICD not mapped genome-wide\", \"Determinants selecting adhesion vs. chemoattraction vs. back-signaling in a given tissue undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [9, 26, 29]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [1, 5]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [12, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 5, 6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 21, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 12, 15, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 15, 16, 20]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CX3CR1\", \"ADAM10\", \"ADAM17\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}